The Clinical and Biomedical Proteomics Group in Leeds is led by Roz Banks and Peter Selby with Nav Vasudev now also taking a lead role in some aspects of renal cancer. The Group is part of the Leeds Institute for Cancer Studies and Pathology which is one of the Leeds Institute of Cancer and Pathology, and is integrated within the Leeds Cancer Research UK Centre and the Leeds Experimental Cancer Medicine Centre. Located on the St James's University Hospital campus and integrated with both the University and Hospital Trust we are ideally placed to pursue translational research. Our main research focus is in the application of proteomic technologies to biomarker discovery, principally in renal cancer and areas of renal medicine such as acute kidney injury and renal transplantation although we are involved in collaborative projects involving genomic/epigenetic approaches and in other clinical areas. Biomarkers have major potential benefit to the patient in contributing to the concept of “personalised medicine”, enabling for example earlier diagnosis, determination of prognosis, selection of optimal treatment and monitoring of response and toxicity. Additionally such research will lead to new insights in disease pathways, facilitating the development of new therapies.
We have state of the art facilities and the capability to cover all aspects of biomarker translation from discovery through to immunoassay development and clinical evaluation at various levels. We also offer proteomic and clinical sample processing research services internally and externally.